| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:74539345:2002 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:74539345:2002?format=raw |
LEADER: 02002fam a2200421 a 4500
001 4059833
005 20221027025851.0
008 980417s1999 gw b 001 0 eng c
010 $a 98004053
020 $a3540636897 (hardcover : alk. paper)
035 $a(OCoLC)39052879
035 $a(OCoLC)ocm39052879
035 $9APG2476HS
035 $a(NNC)4059833
035 $a4059833
040 $aDNLM/DLC$cDLC$dDLC$dNNC-M
050 00 $aRC261$b.R35 vol. 149$aRC280.B6
060 10 $aW1 RE106P v.149 1998$aQZ 267 B6157 1998
082 00 $a616.99/4 s$a616.99/4061$221
245 00 $aBisphosphonates in clinical oncology :$bthe development of pamidronate /$cB. Thürlimann (ed.).
260 $aBerlin ;$aNew York :$bSpringer,$c1999.
300 $axiv, 113 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aRecent results in cancer research,$x0080-0015 ;$v149
504 $aIncludes bibliographical references and index.
650 0 $aDisodium pamidronate.$0http://id.loc.gov/authorities/subjects/sh89003994
650 0 $aBones$xCancer$xChemotherapy.$0http://id.loc.gov/authorities/subjects/sh2010008299
650 0 $aDiphosphonates$xTherapeutic use.
650 12 $aDiphosphonates$xpharmacology.$0https://id.nlm.nih.gov/mesh/D004164Q000494
650 12 $aAntineoplastic Agents$xpharmacology.$0https://id.nlm.nih.gov/mesh/D000970Q000494
650 22 $aHypercalcemia$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D006934Q000188
650 22 $aBone Neoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D001859Q000188
650 22 $aBone Neoplasms$xsecondary.$0https://id.nlm.nih.gov/mesh/D001859Q000556
650 22 $aBone and Bones$xphysiology.$0https://id.nlm.nih.gov/mesh/D001842Q000502
700 1 $aThürlimann, B.$q(Beat),$d1955-$0http://id.loc.gov/authorities/names/n98801265
830 0 $aRecent results in cancer research ;$v149.$0http://id.loc.gov/authorities/names/n42020830
852 00 $boff,hsl$hRC280.B6$iB48 1999